TCR2 Therapeutics Inc. Common Stock, also called TCR2 Therapeutics, is an immunotherapy company, which develops biological drugs and engineering t-cells for cancer therapy. Read More The firm offers cancer therapy, t-cell biology, immunology and molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of t-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA.